No Prescription |
 |
 | ||
|
Exelon Oral Solution Generic Rivastigmine |
|
| ||
No Prescription » Prescription Drugs 7 » Exelon Oral Solution Generic Rivastigmine Rivastigmine is used to treat mild to moderate confusion (dementia) related to Alzheimer's disease. It is also used to treat mild to moderate confusion (dementia) related to Parkinson's disease. Rivastigmine does not cure either of these diseases but it may improve memory awareness and the ability to perform daily functions. This medication works by restoring the balance of natural substances (neurotransmitters) in the brain.Dementia of the Alzheimer's typeThe dosage of Exelon« (rivastigmine tartrate) shown to be effective in controlled clinical trials in Alzheimer's Disease is 6-12 mg/day given as twice-a-day dosing (daily doses of 3 to 6 mg BID). The starting dose of Exelon is 1.5 mg twice a day (BID). If this dose is well tolerated after a minimum of 2 weeks of treatment the dose may be increased to 3 mg BID. Subsequent increases to 4.5 mg BID and 6 mg BID should be attempted after a minimum of 2 weeks at the previous dose. If adverse effects (e.g. nausea vomiting abdominal pain loss of appetite) cause intolerance during treatment the patient should be instructed to discontinue treatment for several doses and then restart at the same or next lower dose level. If treatment is interrupted for longer than several days treatment should be reinitiated with the lowest daily dose and titrated as described above (see WARNINGS). The maximum dose is 6 mg BID (12 mg/day).Dementia associated with Parkinson's DiseaseThe dosage of Exelon« shown to be effective in the single controlled clinical trial conducted in dementia associated with Parkinson's Disease is 3 to 12 mg/day given as twice-a-day dosing (daily doses of 1.5 to 6 mg BID). In that medical condition the starting dose of Exelon« is 1.5 mg BID; subsequently the dose may be increased to 3 mg BID and further to 4.5 mg BID and 6 mg BID based on tolerability with a minimum of 4 weeks at each dose.Exelon should be taken with meals in divided doses in the morning and evening.Recommendations for Administration: Caregivers should be instructed in the correct procedure for administering Exelon Oral Solution. In addition they should be directed to the Instruction Sheet (included with the product) describing how the solution is to be administered. Caregivers should Online questions about the administration of the solution to either their physician or pharmacist. Patients should be instructed to remove the oral dosing syringe provided in its protective case and using the provided syringe withdraw the prescribed amount of Exelon Oral Solution from the container. Each dose of Exelon Oral Solution may be swallowed directly from the syringe or first mixed with a small glass of water cold fruit juice or soda. Patients should be instructed to stir and drink the mixture.Exelon Oral Solution and Exelon Capsules may be interchanged at equal doses. Buy Exelon Oral Solution Generic Rivastigmine and other Prescription Drugs 7 products online at Medstore. 5935
About Exelon Oral Solution Generic Rivastigmine: Product Type: Prescription Drugs 7 Exelon Oral Solution ( Generic Rivastigmine ) Exelon Oral Solution (Generic Rivastigmine) Generic Rivastigmine 2mg/mL 120mL Generic Rivastigmine Exelon Oral Solution
View more Prescription Drugs 7 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
